Literature DB >> 24343961

Post-traumatic stress disorder and the outcome of dialectical behaviour therapy for borderline personality disorder.

Kirsten Barnicot1, Stefan Priebe.   

Abstract

BACKGROUND: Individuals with borderline personality disorder (BPD) and comorbid post-traumatic stress disorder (PTSD) have a worse prognosis than individuals with BPD alone. A common view is that the emotional instability and impulsivity of BPD should be treated before attempting to address trauma. However, PTSD symptoms may interfere with patients' ability to benefit from such 'stabilizing' treatments.
METHODS: The effect of BPD-PTSD comorbidity on self-harm and BPD symptom outcomes was evaluated in 89 patients receiving dialectical behaviour therapy, using multilevel modelling.
RESULTS: Patients with comorbid BPD-PTSD showed a trend towards elevated BPD symptoms throughout the treatment year (β = 2.12, 95% CI = -0.21-4.44, p = 0.07). There was a three-way interaction between PTSD comorbidity, treatment completion and time, whereby PTSD comorbidity was associated with less reduction in self-harm frequency over time, but only in those completing the full 12 months of treatment (incident risk ratio = 1.16, 95% CI = 1.04-1.30, p < 0.01).
CONCLUSION: Patients with comorbid PTSD had a poorer outcome from dialectical behaviour therapy than those with BPD alone, possibly because of the negative impact of unaddressed trauma. The results provide further grounds for recently developed treatments targeting BPD traits and PTSD symptoms simultaneously.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24343961     DOI: 10.1002/pmh.1227

Source DB:  PubMed          Journal:  Personal Ment Health        ISSN: 1932-8621


  8 in total

1.  A pilot randomized controlled trial of Dialectical Behavior Therapy with and without the Dialectical Behavior Therapy Prolonged Exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD.

Authors:  Melanie S Harned; Kathryn E Korslund; Marsha M Linehan
Journal:  Behav Res Ther       Date:  2014-02-11

Review 2.  Psychotherapy for Borderline Personality Disorder: Progress and Remaining Challenges.

Authors:  Paul S Links; Ravi Shah; Rahel Eynan
Journal:  Curr Psychiatry Rep       Date:  2017-03       Impact factor: 5.285

3.  Does Adding the Dialectical Behavior Therapy Prolonged Exposure (DBT PE) Protocol for PTSD to DBT Improve Outcomes in Public Mental Health Settings? A Pilot Nonrandomized Effectiveness Trial With Benchmarking.

Authors:  Melanie S Harned; Sara C Schmidt; Kathryn E Korslund; Robert J Gallop
Journal:  Behav Ther       Date:  2020-09-01

4.  Effectiveness and feasibility of Narrative Exposure Therapy (NET) in patients with borderline personality disorder and posttraumatic stress disorder - a pilot study.

Authors:  Carolin Steuwe; Nina Rullkötter; Verena Ertl; Michaela Berg; Frank Neuner; Thomas Beblo; Martin Driessen
Journal:  BMC Psychiatry       Date:  2016-07-20       Impact factor: 3.630

5.  Borderline personality disorder: patterns of self-harm, reported childhood trauma and clinical outcome.

Authors:  Mark Andrew McFetridge; Rebecca Milner; Victoria Gavin; Liat Levita
Journal:  BJPsych Open       Date:  2015-07-10

Review 6.  What Works in the Treatment of Borderline Personality Disorder.

Authors:  Lois W Choi-Kain; Ellen F Finch; Sara R Masland; James A Jenkins; Brandon T Unruh
Journal:  Curr Behav Neurosci Rep       Date:  2017-02-03

7.  Comorbid Diagnosis of Psychotic Disorders in Borderline Personality Disorder: Prevalence and Influence on Outcome.

Authors:  C W Slotema; Jan D Blom; Marieke B A Niemantsverdriet; Mathijs Deen; Iris E C Sommer
Journal:  Front Psychiatry       Date:  2018-03-14       Impact factor: 4.157

8.  Study protocol: randomized controlled trial of manualized components in home visitation to reduce mothers' risk for child maltreatment.

Authors:  Merel de Wit; Patty Leijten; Claudia van der Put; Jessica Asscher; Merian Bouwmeester-Landweer; Maja Deković
Journal:  BMC Public Health       Date:  2020-01-30       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.